文献速递造血干细胞移植与细胞治疗

病毒特异性T细胞治疗造血干细胞移植后腺病毒感染高效且受II类HLA限制

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
PubMed 文献 · Blood Adv · 2021-01-01

该单中心1/2期临床试验纳入30例异基因造血干细胞移植后腺病毒血症和/或腺病毒病患儿,共输注43次体外制备的病毒特异性T细胞(VSTs)。临床应答率81%,完全应答率58%;对单肽和单HLA转染细胞系的反应证实HLA限制性CD4+ T细胞应答,且与临床结局相关。

要点

  • VSTs治疗移植后腺病毒感染临床应答率81%,完全应答率58%。
  • VSTs可来自干细胞供者或健康第三方供者,安全性高且有效。
  • HLA限制性CD4+ T细胞应答与临床结局相关。

核心结论

  • VSTs是免疫抑制宿主腺病毒感染安全且高效的治疗手段。

研究设计与样本

  • 单中心1/2期临床试验纳入30例异基因造血干细胞移植后腺病毒血症和/或腺病毒病患儿,共输注43次VSTs。

主要发现

  • 7例接受供者来源VSTs,21例接受第三方VSTs,2例接受两种来源VSTs。
  • 临床应答率81%,完全应答率58%。
  • 对单肽和单HLA转染细胞系的反应证实HLA限制性CD4+ T细胞应答,且与临床结局相关。

临床怎么用

  • VSTs可用于异基因造血干细胞移植后腺病毒感染的过继免疫治疗,供者或第三方来源均可考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infection with adenoviruses is a common and significant complication in pediatric patients after allogeneic hematopoietic stem cell transplantation. Treatment options with traditional antivirals are limited by poor efficacy and significant toxicities. T-cell reconstitution is critical for the management of adenoviral infections, but it generally takes place months after transplantation. Ex vivo-generated virus-specific T cells (VSTs) are an alternative approach for viral control and can be rapidly generated from either a stem cell donor or a healthy third-party donor. In the context of a single-center phase 1/2 clinical trial, we treated 30 patients with a total of 43 infusions of VSTs for adenoviremia and/or adenoviral disease. Seven patients received donor-derived VSTs, 21 patients received third-party VSTs, and 2 received VSTs from both donor sources. Clinical responses were observed in 81% of patients, with a complete response in 58%. Epitope prediction and potential epitope identification for common HLA molecules helped elucidate HLA restriction in a subset of patients receiving third-party products. Intracellular interferon-γ expression in T cells in response to single peptides and response to cell lines stably transfected with a single HLA molecule demonstrated HLA-restricted CD4+ T-cell response, and these results correlated with clinical outcomes. Taken together, these data suggest that VSTs are a highly safe and effective therapy for the management of adenoviral infection in immunocompromised hosts. The trials were registered at www.clinicaltrials.gov as #NCT02048332 and #NCT02532452.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rubinstein JD, Zhu X, Leemhuis T, et al. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Blood Adv. 2021. PMID: 34473237. doi:10.1182/bloodadvances.2021004456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。